Biosimilars Archives | Rheumatoid Arthritis Warrior

Biosimilars for Rheumatoid Arthritis: 5 Facts

November 23, 2016October 5, 2019 Kelly O'Neill 8 Comments Biologics for RA, Biosimilars

Click here to answer a Poll on Biosimilars for Rheumatoid Arthritis. New Biosimilars for Rheumatoid Arthritis One of the hottest topics in rheumatology today is biosimilars to for rheumatoid arthritis (RA) and other immune mediated diseases. Dozens of biosimilar medicines are in various stages of development and several are already in use in Europe and Asia. Let’s...Continue reading 8 Comments » Read more

News on Biosimilar Biologics for Rheumatoid Arthritis / Rheumatoid Disease

October 11, 2013May 14, 2018 Kelly O'Neill 1 Comment Biosimilars, Rheumatoid arthritis treatment

Little progress on FDA path of biosimilar biologics for RD It’s hard to believe it’s been almost two years since we’ve discussed biosimilars on Rheumatoid Arthritis Warrior (RAW). What’s even harder to believe: the situation in the U.S. is much the same: 1) The Biologics Price Competition and Innovation Act (BPCI) was created as a pathway for...Continue reading 1 Comment » Read more

Are Biosimilars Justice in Competition for Biologics Like Enbrel?

January 30, 2012May 15, 2018 Kelly O'Neill 13 Comments Biologics for RA, Biosimilars, Rheumatoid arthritis treatment

The FDA definition of biosimilars and a pathway to approval Biosimilars are pharmaceuticals that are similar to biologics such as Enbrel and Humira, but not chemically identical as with generic drugs. If the unique molecules used to create a biologic (from living proteins) such as Enbrel are not cloned, but carefully imitated, they are considered “biosimilar.”...Continue reading 13 Comments » Read more